Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.81 |
| ▸ | ADRB1 | P08588 | 13/20 | 0.63 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | DRD1 | P21728 | 2/20 | 0.58 |
| ▸ | DRD4 | P21917 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009261 | 1.00 | ADRB2 (0.81) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL2009262 | 1.00 | ADRB2 (0.81) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL2008054 | 0.88 | ADRB2 (0.84) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL2008052 | 0.88 | ADRB2 (0.84) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL5970242 | 0.88 | ADRB2 (0.84) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL2008050 | 0.88 | ADRB2 (0.84) | ADRB2ADRB1ADRB3CHRM2DRD2 | |
| SCHEMBL2007309 | 0.87 | ADRB2 (0.85) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL2007307 | 0.87 | ADRB2 (0.85) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL5968563 | 0.87 | ADRB2 (0.85) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL2007310 | 0.87 | ADRB2 (0.85) | ADRB2ADRB1ADRB3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687257-B1 | AMINO-SUBSTITUTED ETHYLAMINO BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-04-15 | — | — | EP | claimed |
| US-7399863-B2 | Amino-substituted ethylamino β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-07-15 | — | — | US | claimed |
| US-20050113411-A1 | Amino-substituted ethylamino beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-05-26 | — | — | US | claimed |
| US-7964730-B2 | Amino-substituted ethylamino β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090111850-A1 | Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-04-30 | — | — | US | disclosed |
| EP-1687257-B1 | AMINO-SUBSTITUTED ETHYLAMINO BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-7399863-B2 | Amino-substituted ethylamino β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20050113411-A1 | Amino-substituted ethylamino beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111850-A1 | Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885ADRB3 6/4885 |
| US-20050113411-A1 | Amino-substituted ethylamino beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885ADRB3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.